Leucine is one of the three branched-chain amino acids (BCAAs) — the amino acids that share a branched side chain structure and that are oxidised directly in the skeletal muscle rather than in the liver, making them uniquely important for muscle energy metabolism and for the regulation of muscle protein synthesis. Leucine is the primary nutrient signal that activates the mTOR (mechanistic target of rapamycin) pathway in skeletal muscle — the master regulatory pathway of muscle protein synthesis that drives the growth, repair, and regeneration of skeletal muscle in response to protein intake, resistance exercise, and the other anabolic stimuli that maintain muscle mass throughout the lifespan. Without adequate leucine, the mTOR pathway is not activated, muscle protein synthesis is impaired, and the muscle undergoes the progressive atrophy that characterises sarcopenia — the age-related loss of muscle mass and function that is one of the most important determinants of functional decline, disability, and mortality in older adults.
The mTOR Pathway and Muscle Protein Synthesis
The mTOR pathway is the master regulator of cell growth and protein synthesis in all eukaryotes — it integrates signals from nutrients (particularly leucine and other essential amino acids), from growth factors (particularly insulin and IGF-1), and from cellular energy status ( AMPK is activated when ATP is low, which inhibits mTOR) to determine whether the cell should be in a growth state or in a catabolic state. In skeletal muscle, mTOR is activated by leucine binding to the leucine-binding protein sestrin2, which releases mTOR from its inhibitor (the GAP activity towards Rags 1A protein, GATOR1) and allows mTOR to translocate to the lysosomal surface where its downstream targets are located. Activated mTOR then phosphorylates its two primary downstream targets — S6 kinase 1 (S6K1, which phosphorylates the ribosomal protein S6 and initiates the translation of the mRNA that encodes the components of the translational machinery) and eukaryotic initiation factor 4E binding protein 1 (4E-BP1, which is released from eIF4E and allows the initiation of translation of the mRNAs that are required for protein synthesis).
The clinical importance of the leucine-mTOR axis for muscle health is underscored by the effects of leucine supplementation in older adults. Ageing is associated with a blunting of the muscle protein synthetic response to amino acid intake (the anabolic resistance of ageing muscle), and this blunting is thought to be a primary mechanism of sarcopenia. Studies in older adults show that leucine supplementation at 2.5-3g per meal (as opposed to the standard BCAA mixtures, which typically contain equal parts leucine, isoleucine, and valine) produces a robust activation of the mTOR pathway and a significant improvement in the muscle protein synthetic response to protein intake. A double-blind RCT in 40 older adults found that leucine supplementation at 2.5g daily (with each main meal) for 8 weeks significantly improved muscle mass, muscle strength, and physical function compared to placebo — with benefits that were apparent within the first 4 weeks of treatment.
Leucine and Glucose Metabolism
Leucine has specific effects on glucose metabolism that extend beyond its role in muscle protein synthesis. Leucine activates the mTOR pathway in pancreatic beta cells (where it stimulates insulin synthesis and secretion), and it inhibits the autophagy pathway (which is the cellular process by which damaged proteins and organelles are removed and recycled). The effects of leucine on beta cell function are clinically relevant for the management of type 2 diabetes — studies in people with type 2 diabetes show that leucine supplementation improves insulin secretion and reduces fasting blood glucose levels, particularly when combined with adequate protein intake. The inhibition of autophagy by leucine also has implications for cancer metabolism — mTOR inhibition (which is produced by leucine depletion) activates autophagy, and some cancer therapies are designed to activate autophagy as a way of triggering cancer cell death.
Practical Application
For muscle protein synthesis support and for the prevention of sarcopenia, the evidence-based dose is 2-3g of leucine daily, taken with each main meal that contains protein (at doses of approximately 25-40g of protein per meal, to provide the full complement of essential amino acids along with the leucine signal). The most common supplement form is L-leucine powder, which can be added to protein shakes or mixed with food. Leucine is generally well-tolerated with no significant adverse effects at doses up to 10g daily, though very high doses (above 5g per single dose) can produce GI discomfort. For comprehensive muscle health support, leucine pairs well with the other essential amino acids (to provide the complete set of substrates for protein synthesis), with resistance exercise (which synergises with leucine to activate the mTOR pathway), with adequate vitamin D status (which is required for the transcription of the muscle-specific genes that are activated during muscle hypertrophy), and with the omega-3 fatty acids (which have anti-inflammatory effects that reduce the muscle protein breakdown that is associated with chronic inflammation in older adults).
Leave a Reply